HC Wainwright Forecasts Strong Price Appreciation for Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S (NASDAQ:GMAB) had its price target lifted by HC Wainwright from $36.00 to $40.00 in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on GMAB. Wall Street Zen raised shares of Genmab A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 26th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price for the company in a report on Tuesday, September 23rd. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Truist Financial raised their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.80.

Genmab A/S Trading Up 4.5%

GMAB stock opened at $33.56 on Thursday. The stock’s 50 day simple moving average is $25.84 and its 200 day simple moving average is $22.44. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $33.61. The firm has a market cap of $21.53 billion, a P/E ratio of 16.86, a P/E/G ratio of 1.90 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. On average, research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently modified their holdings of the stock. Foresight Group Ltd Liability Partnership acquired a new position in shares of Genmab A/S in the 1st quarter worth $954,000. Vident Advisory LLC purchased a new position in Genmab A/S in the 1st quarter worth about $242,000. GAMMA Investing LLC increased its stake in Genmab A/S by 1,465.3% in the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock worth $656,000 after purchasing an additional 31,343 shares in the last quarter. Fifth Third Bancorp raised its holdings in Genmab A/S by 16.6% during the 1st quarter. Fifth Third Bancorp now owns 42,151 shares of the company’s stock worth $825,000 after buying an additional 6,015 shares during the period. Finally, Parallel Advisors LLC lifted its stake in Genmab A/S by 377.5% during the second quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock valued at $77,000 after buying an additional 2,941 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.